Guided Therapeutics (GTHP) and Its Competitors Head to Head Review

Guided Therapeutics (OTCMKTS:GTHP) is one of 75 public companies in the “Electromedical equipment” industry, but how does it weigh in compared to its peers? We will compare Guided Therapeutics to related companies based on the strength of its institutional ownership, analyst recommendations, valuation, risk, earnings, profitability and dividends.

Profitability

This table compares Guided Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-138.23%
Guided Therapeutics Competitors	-322.42%	-89.80%	-29.27%

Analyst Ratings

This is a breakdown of recent recommendations for Guided Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
Guided Therapeutics Competitors	264	797	1998	109	2.62

As a group, “Electromedical equipment” companies have a potential upside of 3,082.85%. Given Guided Therapeutics’ peers higher probable upside, analysts plainly believe Guided Therapeutics has less favorable growth aspects than its peers.

Insider and Institutional Ownership

9.7% of Guided Therapeutics shares are held by institutional investors. Comparatively, 43.2% of shares of all “Electromedical equipment” companies are held by institutional investors. 66.8% of Guided Therapeutics shares are held by insiders. Comparatively, 15.1% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Guided Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ peers have a beta of 0.84, meaning that their average stock price is 16% less volatile than the S&P 500.

Earnings & Valuation

This table compares Guided Therapeutics and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Guided Therapeutics	$100,000.00	-$3.49 million	-4.34
Guided Therapeutics Competitors	$1.00 billion	$84.14 million	84.31

Guided Therapeutics’ peers have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Guided Therapeutics peers beat Guided Therapeutics on 7 of the 10 factors compared.

About Guided Therapeutics

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.